Serum lipoprotein(a) levels and apolipoprotein(a) isoform size and risk for first-ever acute ischaemic nonembolic stroke in elderly individuals.

[1]  D. Mikhailidis,et al.  Components of the Metabolic Syndrome and Risk for First-Ever Acute Ischemic Nonembolic Stroke in Elderly Subjects , 2005, Stroke.

[2]  A. Gaw,et al.  Plasma lipoprotein(a) [Lp(a)] concentrations and cardiovascular events in the elderly: evidence from the prospective study of pravastatin in the elderly at risk (PROSPER). , 2005, Atherosclerosis.

[3]  H. Milionis,et al.  Risk factors for first-ever acute ischemic non-embolic stroke in elderly individuals. , 2005, International journal of cardiology.

[4]  A. Scanu.  Lp(a) lipoprotein--coping with heterogeneity. , 2003, The New England journal of medicine.

[5]  A. Ariyo,et al.  Lp(a) lipoprotein, vascular disease, and mortality in the elderly. , 2003, The New England journal of medicine.

[6]  G. Valenti,et al.  The role of lipid profile in determining the risk of ischemic stroke in the elderly: a case-control study. , 2003, Archives of gerontology and geriatrics.

[7]  A. Tsatsoulis,et al.  Lipoprotein (a) levels and apolipoprotein (a) isoform size in patients with subclinical hypothyroidism: effect of treatment with levothyroxine. , 2003, Thyroid : official journal of the American Thyroid Association.

[8]  P. Macfarlane,et al.  Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial , 2002, The Lancet.

[9]  A. Evans,et al.  Lipoprotein (a) as a predictor of coronary heart disease: the PRIME Study. , 2002, Atherosclerosis.

[10]  G. Somay,et al.  Relation of lipid and lipoprotein(a) to ischaemic stroke , 2002, Journal of Clinical Neuroscience.

[11]  R. Sacco,et al.  Relation of Apo(a) Size to Carotid Atherosclerosis in an Elderly Multiethnic Population , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[12]  S. Yusuf.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary , 2002 .

[13]  Lipoprotein(a) further increases the risk of coronary events in men with high global cardiovascular risk. , 2001, Journal of the American College of Cardiology.

[14]  H. Milionis,et al.  Lipoprotein (a) and stroke , 2000, Journal of clinical pathology.

[15]  L. Lemberg,et al.  Stroke risk, cholesterol and statins. , 1999, American journal of critical care : an official publication, American Association of Critical-Care Nurses.

[16]  L. Weinehall,et al.  Chlamydia pneumoniae antibodies and high lipoprotein(a) levels do not predict ischemic cerebral infarctions. Results from a nested case-control study in Northern Sweden. , 1999, Stroke.

[17]  I. Ford,et al.  Impact of apo(a) length polymorphism and the control of plasma Lp(a) concentrations: evidence for a threshold effect. , 1998, Arteriosclerosis, thrombosis, and vascular biology.

[18]  K. Bailey,et al.  Predictive value of electrophoretically detected lipoprotein(a) for coronary heart disease and cerebrovascular disease in a community-based cohort of 9936 men and women. , 1997, Circulation.

[19]  P. Wilson,et al.  Elevated plasma lipoprotein(a) and coronary heart disease in men aged 55 years and younger. A prospective study. , 1996, JAMA.

[20]  K. Kario,et al.  'Silent' cerebral infarction is associated with hypercoagulability, endothelial cell damage, and high Lp(a) levels in elderly Japanese. , 1996, Arteriosclerosis, thrombosis, and vascular biology.

[21]  M. Margaglione,et al.  Plasma lipoprotein(a) levels in subjects attending a metabolic ward. Discrimination between individuals with and without a history of ischemic stroke. , 1996, Arteriosclerosis, thrombosis, and vascular biology.

[22]  P. Ridker,et al.  Plasma concentration of lipoprotein(a) and the risk of future stroke. , 1995, JAMA.

[23]  L. Chambless,et al.  Lipoprotein(a) as a correlate of stroke and transient ischemic attack prevalence in a biracial cohort: the ARIC Study. Atherosclerosis Risk in Communities. , 1994, Annals of epidemiology.

[24]  R. Muche,et al.  Lipoprotein Lp(a) as predictor of myocardial infarction in comparison to fibrinogen, LDL cholesterol and other risk factors: results from the prospective Göttingen Risk Incidence and Prevalence Study (GRIPS) , 1994, European journal of clinical investigation.

[25]  K. Kario,et al.  Close relation between lipoprotein (a) levels and atherothrombotic disease in Japanese subjects > 75 years of age. , 1994, The American journal of cardiology.

[26]  J. Salonen,et al.  Relation of serum homocysteine and lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finnish population based study. , 1994, Atherosclerosis.

[27]  H. Hamaguchi,et al.  High Serum Lipoprotein (a) Levels Are an Independent Risk Factor for Cerebral Infarction , 1993, Stroke.

[28]  E. Boerwinkle,et al.  Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations. , 1992, The Journal of clinical investigation.

[29]  Ruth Bonita,et al.  Epidemiology of stroke , 1992, The Lancet.

[30]  R. Kronmal,et al.  The Cardiovascular Health Study: design and rationale. , 1991, Annals of epidemiology.